Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD

Jan Stolk, Naveh Tov, Kenneth R. Chapman, Pablo Fernandez, William MacNee, Nicholas S. Hopkinson, Eeva Piitulainen, Niels Seersholm, Claus F. Vogelmeier, Robert Bals, Gerry McElvaney, Robert A. Stockley
European Respiratory Journal 2019 54: 1900673; DOI: 10.1183/13993003.00673-2019
Jan Stolk
1Dept of Pulmonology, Member of European Reference Network LUNG, Leiden University Medical Centre, Leiden, NL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: j.stolk@lumc.nl
Naveh Tov
2Dept of Clinical Development, Kamada Ltd, Rehovot, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth R. Chapman
3Dept of Medicine, University of Toronto, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kenneth R. Chapman
Pablo Fernandez
4Independent Consultant, Penn, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William MacNee
5University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas S. Hopkinson
6National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas S. Hopkinson
Eeva Piitulainen
7Dept of Respiratory Medicine and Allergology, Malmö, Skane University Hospital, Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niels Seersholm
8Dept of Respiratory Medicine Y, Gentofte University Hospital, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claus F. Vogelmeier
9Dept of Medicine, Pulmonary and Critical Care Medicine, Member of the German Center for Lung Diseases (DZL), University Medical Centre Giessen and Marburg, Philipps-University Marburg, Marburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Bals
10Internal Medicine V - Pulmonology, Member of the German Center for Lung Diseases (DZL), Hospital of the University of the Saarland, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Bals
Gerry McElvaney
11Dept of Respiratory Medicine, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Stockley
12Queen Elizabeth Hospital, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructive pulmonary disease (COPD) frequently experience exacerbations. We postulated that inhalation of nebulised AAT would be an effective treatment.

We randomly assigned 168 patients to receive twice-daily inhalations of 80 mg AAT solution or placebo for 50 weeks. Patients used an electronic diary to capture exacerbations. The primary endpoint was time from randomisation to the first event-based exacerbation. Secondary endpoints included change in the nature of the exacerbation as defined by the Anthonisen criteria. Safety was also assessed.

Time to first moderate or severe exacerbation was a median of 112 days (interquartile range (IQR) 40–211 days) for AAT and 140 days (IQR 72–142 days) for placebo (p=0.0952). The mean yearly rate of all exacerbations was 3.12 in the AAT-treated group and 2.67 in the placebo group (p=0.31). More patients receiving AAT reported treatment-related treatment-emergent adverse events compared to placebo (57.5% versus 46.9%, respectively) and they were more likely to withdraw from the study. After the first year of the study, when modifications to the handling of the nebuliser were introduced, the rate of safety events in the AAT-treated group dropped to that of the placebo group.

We conclude that in AATD patients with severe COPD and frequent exacerbations, AAT inhalation for 50 weeks showed no effect on time to first exacerbation but may have changed the pattern of the episodes.

Abstract

Inhaled α1-antitrypsin did not significantly reduce the time to first exacerbation in patients with severe α1-antitrypsin deficiency who experience frequent exacerbations of COPD in a randomised placebo-controlled clinical trial of 1 year http://bit.ly/2P5zXdK

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

    This study is registered as clinical trial NCT01217671. Readers may request the data from N. Tov, who is a co-author of this manuscript.

  • Author contributions: J. Stolk was involved in the design of the study, was principal investigator for Leiden University Medical Centre and collected data from study patients. He was involved in data analysis and interpretation and wrote the article in collaboration with N. Tov, P. Fernandez and R.A. Stockley. N. Tov was involved in the design of the study and oversight of study conduct. He was involved in data analysis and interpretation, and wrote the article in collaboration with other co-authors. K.R. Chapman was principal investigator for his site and collected data from study patients. He was involved in data analysis and contributed to the article. P. Fernandez was involved in the design of the study. He analysed the diary cards and was involved in data analysis and interpretation and contributed to the article. W. MacNee was principal investigator for his site and collected data from study patients. He was involved in data analysis and contributed to the article. N.S. Hopkinson was principal investigator for his site and collected data from study patients. He was involved in data analysis and contributed to the article. E. Piitulainen was principal investigator for her site and collected data from study patients. She was involved in data analysis and contributed to the article. N. Seersholm was principal investigator for his site and collected data from study patients. He was involved in data analysis and contributed to the article. C.F. Vogelmeier was principal investigator for his site and collected data from study patients. He was involved in data analysis and contributed to the article. R. Bals was principal investigator for his site and collected data from study patients. He was involved in data analysis and contributed to the article. G. McElvaney was principal investigator for his site and collected data from study patients. He was involved in data analysis and contributed to the article. R.A. Stockley was involved in the design of the study, was principal investigator for his site, and collected data from study patients. He analysed the diary cards and was involved in data analysis and interpretation and wrote the article in collaboration with N. Tov, P. Fernandez, and J. Stolk.

  • Conflict of interest: J. Stolk reports personal fees for consultancy from Kamada Ltd, during the conduct of the study, and grants from CSL Behring, outside the submitted work.

  • Conflict of interest: N. Tov reports personal fees for consultancy from Kamada Ltd, during the conduct of the study, and is an employee of Kamada Ltd, outside the submitted work.

  • Conflict of interest: K.R. Chapman reports personal fees for consultancy from Kamada Ltd, during the conduct of the study, and grants from CSL Behring and Grifols, outside the submitted work.

  • Conflict of interest: P. Fernandez reports consultancy fees from Kamada Ltd, during the planning, design, conduct and reporting of the study.

  • Conflict of interest: W. MacNee reports patient recruitment fees from Kamada Ltd, during the conduct of the study; and grants and personal fees from Pfizer and GlaxoSmithKline, and personal fees from Boehringer Ingelheim, AstraZeneca, Novartis, Zambon and Chiesi, outside the submitted work.

  • Conflict of interest: N.S. Hopkinson has nothing to disclose.

  • Conflict of interest: E. Piitulainen has nothing to disclose.

  • Conflict of interest: N. Seersholm has nothing to disclose.

  • Conflict of interest: C.F. Vogelmeier reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols and Novartis, and personal fees from CSL Behring, Chiesi, Menarini, Mundipharma, Teva and Cipla, outside the submitted work.

  • Conflict of interest: R. Bals reports grants from Kamada Ltd, during the conduct of the study; and grants from BMBF, DFG, Schwiete Stiftung, Sander-Stiftung and Boehringer Ingelheim, and personal fees for advisory board work and travel to meetings from GlaxoSmithKline, CSL Behring, Boehringer Ingelheim, Grifols, AstraZeneca and Novartis, outside the submitted work.

  • Conflict of interest: G. McElvaney reports personal fees for advisory board work from CSL Behring, grants and personal fees for advisory board work from Grifols, and grants from Chiesi, outside the submitted work.

  • Conflict of interest: R.A. Stockley reports personal fees for advisory board membership from Kamada Ltd, during the conduct of the study; personal fees for advisory board membership and lectures from AstraZeneca, personal fees for advisory board membership from Medimmune, Almirall, Baxter, Chiesi and Polyphor, personal fees for lectures from Nycomed and Takeda, and personal fees for advisory board membership, lectures and travel to meetings from Boehringer Ingelheim and CSL Behring, outside the submitted work.

  • Support statement: Kamada Ltd was the sponsor of the study and delivered all data obtained during the clinical trial and all statistical analyses to all authors. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received May 21, 2018.
  • Accepted August 13, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 5 Table of Contents
European Respiratory Journal: 54 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD
Jan Stolk, Naveh Tov, Kenneth R. Chapman, Pablo Fernandez, William MacNee, Nicholas S. Hopkinson, Eeva Piitulainen, Niels Seersholm, Claus F. Vogelmeier, Robert Bals, Gerry McElvaney, Robert A. Stockley
European Respiratory Journal Nov 2019, 54 (5) 1900673; DOI: 10.1183/13993003.00673-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD
Jan Stolk, Naveh Tov, Kenneth R. Chapman, Pablo Fernandez, William MacNee, Nicholas S. Hopkinson, Eeva Piitulainen, Niels Seersholm, Claus F. Vogelmeier, Robert Bals, Gerry McElvaney, Robert A. Stockley
European Respiratory Journal Nov 2019, 54 (5) 1900673; DOI: 10.1183/13993003.00673-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • EmPHasis-10 as a measure of quality of life in PAH
  • EmPHasis-10 health-related quality of life score predicts outcomes in PAH
  • Periostin and airway epithelial function in asthma
Show more Original Articles

COPD

  • OSTEOPOROSIS AND FACTURE RISK ASSOCIATED WITH ICS USE IN COPD
  • Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
  • Metered cryospray for patients with chronic bronchitis in COPD
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society